The FDA Is Making It Harder to Quit Smoking

The article argues that the FDA's regulatory approach to tobacco and vaping products is counterproductive, making it harder rather than easier for smokers to quit. While cigarettes, which cause the overwhelming majority of tobacco-related disease, remain widely available with minimal regulatory surveillance, less harmful alternatives like e-cigarettes face flavor bans and one of the FDA's most restrictive approval processes. As of May, the FDA had authorized only 45 e-cigarette products, and even flavored vaping approvals come with extraordinary conditions such as random biometric checks.

The article cites evidence supporting vaping as a less harmful alternative and effective cessation tool. The Royal College of Physicians' 2024 review concluded that vaping exposes users to substantially lower levels of toxic chemicals than smoking and recommends e-cigarettes as a smoking-cessation treatment, including flavored options. A 2025 review of 104 studies involving over 30,000 adults found high-certainty evidence that nicotine e-cigarettes produce higher cessation rates than traditional nicotine-replacement therapies like patches and gum.

The article also challenges the justification for restrictions based on youth nicotine use. According to the FDA's 2025 National Youth Tobacco Survey, tobacco use among middle and high school students actually fell between 2022 and 2025, with e-cigarette use dropping from over 9 percent to 5.2 percent and cigarette smoking at just 1.4 percent. The author argues that restricting flavored vaping products can backfire: a 2024 study of nearly 377,000 young adults found flavor restrictions were associated with a 2.2-percentage-point increase in daily cigarette smoking, and San Francisco's flavor ban was linked to increased cigarette smoking among high school students.

The article recommends a proportional, risk-based regulatory approach: enforcing existing age restrictions, establishing product-safety standards, policing misleading health claims, and creating a predictable approval pathway for vaping products that asks whether they are substantially less harmful than smoking and help smokers quit. The author concludes that the goal of tobacco policy should be to reduce disease and premature death, not to protect the most dangerous product on the market from safer competitors. For smokers who cannot quit nicotine entirely, switching from combustible cigarettes to less harmful alternatives represents a major health improvement.

(Source：RealClearHealth)